Zentalis Pharmaceuticals (ZNTL) Change in Receivables (2019 - 2025)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Change in Receivables of -$5.0 million for Q1 2025, down 200.0% quarter-over-quarter from $5.0 million in Q4 2024.
Analysis
Zentalis Pharmaceuticals (ZNTL) Change in Receivables (2019 - 2025) Analysis & Trends
Zentalis Pharmaceuticals' Change in Receivables history runs 6 years deep, the most recent figure standing at -$5.0 million for Q1 2025.
- In Q1 2025, Change in Receivables changed N/A year-over-year to -$5.0 million; the TTM figure through Dec 2025 stood at -$5.0 million (down 200.0% YoY), while the FY2025 annual figure was -$5.0 million, down 200.0% from the prior year.
- Change in Receivables for Q1 2025 stood at -$5.0 million, down from $5.0 million in the prior quarter.
- The five-year high for Change in Receivables was $5.0 million in Q4 2024, with the low at -$5.0 million in Q1 2025.
- The 4-year median for Change in Receivables is -$104000.0 (2021), against an average of -$58428.6.
- Peak annual rise in Change in Receivables reached 110.2% in 2021, while the deepest fall reached 16800.0% in 2021.
- Zentalis Pharmaceuticals' Change in Receivables stood at -$104000.0 in 2021, then jumped by 103.85% to $4000.0 in 2022, then surged by 124900.0% to $5.0 million in 2024, then slumped by 200.0% to -$5.0 million in 2025.
- Business Quant data shows ZNTL's Change in Receivables at -$5.0 million in Q1 2025, $5.0 million in Q4 2024, and $4000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Zentalis Pharmaceuticals | 282.81 Mn | 282.81 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | -5.00 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Dec 31, 2022 | 4,000.00 |
| Dec 31, 2021 | -104,000.00 |
| Sep 30, 2021 | 103,000.00 |
| Jun 30, 2021 | -243,000.00 |
| Mar 31, 2021 | -169,000.00 |
| Dec 31, 2020 | 295,000.00 |
| Sep 30, 2020 | 49,000.00 |
| Jun 30, 2020 | -66,000.00 |
| Mar 31, 2020 | -1,000.00 |
| Dec 31, 2019 | 90,000.00 |
| Sep 30, 2019 | -270,000.00 |
| Jun 30, 2019 | -372,000.00 |
| Mar 31, 2019 | -225,000.00 |